4 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow CV Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L HT1001 extract of Panax quinquefolius L - Memory, Learning | Phase 2 | Completed | CV Technologies | 72 | 2007-07-01 | 2008-03-12 |
| Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults CVT E002 (Cold-fX) - Healthy | Phase 2 | Completed | CV Technologies | 50 | 2007-03-01 | 2007-07-17 |
| Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults CVT-E002 (Cold-FX); a natural health product - Upper Respiratory Infection | Phase 3 | Completed | CV Technologies | 500 | 2005-12-01 | 2009-06-08 |
| Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection. CVT-E002 ginseng extract - Upper Respiratory Infection | Phase 2 | Completed | CV Technologies | 75 | 2005-11-01 | 2007-06-18 |
Common Cold (2) · Influenza, Human (2) · Respiratory Tract Infections (2)
COLD-fX (2)
Canada (3) · United States (1)
Gerry Predy, MD (1) · Scot E Purdon, PhD (1) · Steven Sperber, MD (1) · Sunita Vohra, MD (1)